Yihong Zhang
Overview
Explore the profile of Yihong Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
1023
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu H, Wang X, Li B, Xiang Z, Zhao Y, Lu M, et al.
Cancer Lett
. 2025 Feb;
616:217532.
PMID: 40021040
Dysregulated autophagy has been implicated in the pathogenesis of numerous diseases, including cancer. Despite extensive research on the underlying mechanisms of autophagy, the involvement of long non-coding RNAs (lncRNAs) remains...
2.
Li C, Gu S, Zhang Y, Zhang Z, Wang J, Gao T, et al.
Therap Adv Gastroenterol
. 2025 Feb;
18:17562848251318833.
PMID: 39963253
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is characterized by chronic nonspecific intestinal inflammation. Despite considerable efforts, IBD remains a heavy burden on society and human health,...
3.
Lu H, Sun D, Wang Z, Cui H, Min L, Zhang H, et al.
J Med Chem
. 2025 Feb;
68(4):4148-4167.
PMID: 39948720
Cyclin-dependent kinases 12 and 13 (CDK12/13) safeguard genomic integrity by preferentially regulating gene expression in the DNA damage response (DDR). The CDK12/13-mediated upregulation of DDR genes and pathways significantly contributes...
4.
Wang Y, Zhang Y, Liu J, Zhao J, Wang C, Meng F, et al.
J Med Chem
. 2025 Jan;
68(3):3886-3899.
PMID: 39885813
Fibroblast growth factor receptors (FGFRs) are established oncogenic drivers in various solid tumors. However, the approved FGFR inhibitors face challenges with acquired resistance and dose-limiting adverse effects associated with FGFR1/4...
5.
Zhou M, Feng J, Mei Q, Li T, Zhang Y, Liu W, et al.
Small
. 2025 Jan;
21(8):e2409363.
PMID: 39828616
Complexity of tumor and its microenvironment as obstacles often restrict traditional tumor therapies. Enzyme/nanozyme-mediated catalytic therapy has been emerged, but the efficacy of single catalytic therapy is still moderate. Inspired...
6.
Microenvironmental modulation breaks intrinsic pH limitations of nanozymes to boost their activities
Li T, Wang X, Wang Y, Zhang Y, Li S, Liu W, et al.
Nat Commun
. 2024 Dec;
15(1):10861.
PMID: 39738107
Functional nanomaterials with enzyme-mimicking activities, termed as nanozymes, have found wide applications in various fields. However, the deviation between the working and optimal pHs of nanozymes has been limiting their...
7.
Li F, Zhang Y, Fang Y, Chen Z
Eur Child Adolesc Psychiatry
. 2024 Dec;
PMID: 39652173
Early-onset generalized anxiety symptoms have severe impacts on youth development. Age differences in anxiety symptoms are obscure. Effective intervention targets need further investigation. Adolescents and emerging adults (N = 65,048;...
8.
Zhou M, Muhammad F, Zhang Y, Li T, Feng J, Zhao J, et al.
Chem Sci
. 2024 Dec;
16(10):4226-4236.
PMID: 39620075
Copper homeostasis is crucial for cells, especially for rapidly proliferating cancerous cells. Copper imbalance-induced cell death (, cuproptosis) has emerged as a new strategy for tumor therapy. While copper accumulation-induced...
9.
Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide
Zhang Y, El Harchi A, James A, Oiki S, Dempsey C, Hancox J
Cell Mol Life Sci
. 2024 Nov;
81(1):466.
PMID: 39607488
Potassium channels encoded by human Ether-à-go-go-Related Gene (hERG) are inhibited by diverse cardiac and non-cardiac drugs. Disopyramide is a chiral Class Ia antiarrhythmic that inhibits hERG at clinical concentrations. This...
10.
Lu H, Zhang Y, Liu J, Jiang T, Yu X, Zhang H, et al.
J Med Chem
. 2024 Nov;
67(22):20580-20594.
PMID: 39520367
Cyclin-dependent kinase 7 (CDK7) is a key regulator of the cell cycle and transcription, making it a promising target for cancer therapy. Although current CDK7 inhibitors have improved in their...